Astellas Paying $5.9bn For Iveric To Boost Ophthalmology Presence
Eyes Post-Xtandi Revenues
Astellas set to acquire private US firm to add to its strategic capabilities in ophthalmology focus area, along with another revenue pillar as it prepares for Xtandi expiry.
You may also be interested in...
The success of Enhertu led Daiichi Sankyo to raise its annual forecast for the fiscal year ending 31 March, while Eisai is readying for Leqembi’s steady US growth. Meanwhile, Astellas, Chugai and Shionogi balanced growth for some products with declines for others.
Daily notebook from the J.P. Morgan Healthcare Conference: Novo makes its debut appearance and welcomes newcomers to the obesity market; Novartis weighs its options in obesity; Lilly expects donanemab to launch into a primed Alzheimer's market – and it continues to look for more large-market opportunities; and Apellis sees strong 2023 Syfovre sales.
The C5 inhibitor, recently acquired by Astellas, will be commercially available in two to four weeks and will compete against Apellis Pharma’s Syfovre.